Armata Pharmaceuticals 3Q 2026: Revenue $3.17M, EPS ($0.24) — 10-Q Summary
Armata Pharmaceuticals reported 3Q 2026 revenue of $3.17M, up 173.6% YoY, and net income of $42.64M, reversing a prior-year loss. The gain was driven by higher grant revenue and a $69.6M increase in the fair value of the Convertible Loan, offset by increased expenses. FDA granted Breakthrough Therapy designation for AP-SA02, and Phase 3 preparation is underway.



